MEGAN WATHEN: Open Payments
NPI 1538945431 · EVANSVILLE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$685 in 42 payments from 15 companies in 2025. Trend: 2023 $138 · 2024 $504 · 2025 $685
Food & beverage: $685
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $213 |
| Otsuka America Pharmaceutical, Inc. | 3 | $73 |
| Axsome Therapeutics, Inc. | 2 | $56 |
| Lilly USA, LLC | 3 | $54 |
| PFIZER INC. | 2 | $45 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Novo Nordisk Inc | 2 | $34 |
| Astellas Pharma US Inc | 1 | $26 |
| Ardelyx, Inc. | 1 | $21 |
Products named: UBRELVY, REXULTI, Auvelity, QULIPTA, VRAYLAR, CAPLYTA, Ozempic, MOUNJARO.
Industry payments across IN — which companies pay providers there.
